Advancements in pharmaceutical sector is expected to drive market expansion in the near future at a CAGR of 9.40% during the forecast period 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Hydroxypropyl Methylcellulose Capsules Market” that contains information from 2018 to 2032. The hydroxypropyl methylcellulose capsules market is estimated to register a CAGR of 9.40% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global hydroxypropyl methylcellulose capsules market— ACG Worldwide Pvt., Ltd., BioCaps Enterprise, Bright Caps GmbH, Bright Pharmacaps Inc., Capscanada Corporation, Capsugel, Inc., Excellent Health Products Co., Ltd., Farmacapsulas S.A., Healthcaps India Limited, Natural Capsules Ltd., Qualicaps, Inc., Shanghai Honest Chem Co., Ltd., Shaoxing Kangke Capsule Co., Ltd., Suheung Co Ltd., Sunil Healthcare, Wuhan Carma Technology Co., Ltd, Zhejiang Yuexi Capsule Co., Ltd. and others.

Hydroxypropyl Methylcellulose Capsules Market Highlights

The global Hydroxypropyl methylcellulose capsules market is accounted to register a CAGR of 9.40% during the forecast period and is estimated to reach USD 0.861 Billion by 2032.

The market for hydroxypropyl methylcellulose (HPMC) capsules is expanding, driven by the pharmaceutical and nutraceutical industries. These capsules are widely used as an alternative to traditional gelatin capsules, appealing to vegetarian and vegan consumers. HPMC capsules offer stability, customization, and compatibility with a range of formulations, contributing to their market growth.

Segment Analysis

The global hydroxypropyl methylcellulose capsules market has been segmented based product and end-user.

On the basis of product, the market is segmented into with gelling aid and without gelling aid. The without gelling aid segment dominated the market in 2022. Individuals without the use of gelling agents can consume HPMC capsules if they have specific dietary restrictions or allergies, such as gelatin allergies.   

Based on end-user, the global hydroxypropyl methylcellulose capsules market has been segmented into pharmaceutical companies, CMO's (Contract manufacturing organizations), food and beverage companies and cosmetic companies. The pharmaceutical companies category generated the most income in 2022. Regulatory organizations like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved HPMC capsules for use in pharmaceutical products.

Regional Analysis

The global hydroxypropyl methylcellulose capsules market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe hydroxypropyl methylcellulose capsules market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Hydroxypropyl methylcellulose capsules market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Hydroxypropyl methylcellulose capsules market comprises of Middle East, Africa, and Latin America.

The North America Hydroxypropyl methylcellulose capsules Market dominated this market in 2022 (45.80%). The reputation of North America, and particularly the United States, for having stringent regulatory standards upheld by the U.S. FDA, is well-known. The demand for HPMC capsules in this region is being driven by the necessity to abide by these strict regulations. Because the FDA approves of HPMC capsules, they are a popular choice for pharmaceutical companies looking to enter or expand in the North American market.

Moreover, Europe holds the second-largest market share for hydroxypropyl methylcellulose capsules. Overseeing a standard regulatory framework for pharmaceutical products in Europe is the European Medicines Agency (EMA). The fact that HPMC capsules adhere to European standards makes them an appealing alternative for pharmaceutical companies with operations throughout numerous European countries. The ease of obtaining approvals contributes to the widespread use of HPMC capsules in Europe.

Additionally, The Asia-Pacific Hydroxypropyl methylcellulose capsules Market is expected to grow at the fastest CAGR from 2023 to 2032. In many Asian countries, traditional medicine and herbal remedies are frequently employed in healthcare. Herbal extracts and conventional treatments are packed in HPMC capsules to suit the need for natural and holistic healthcare solutions.

Furthermore, the rest of the world's Hydroxypropyl methylcellulose capsules market is divided into the Middle East, Africa, and Latin America. Latin America's pharmaceutical and nutraceutical sectors are adopting hydroxypropyl methylcellulose (HPMC) capsules due to their suitability for diverse formulations and dietary preferences. These capsules cater to vegetarian and vegan consumers, aligning with the region's varied dietary choices.

Key Findings of the Study

• The global hydroxypropyl methylcellulose capsules market is expected to reach USD 0.861 Billion by 2032, at a CAGR of 9.40% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market Traditional medicine and herbal treatments are widely used in healthcare across many Asian nations. To meet the need for natural and holistic healthcare solutions, herbal extracts and conventional treatments are encapsulated in HPMC capsules.


• Based on product, the without gelling aid segment was attributed to holding the largest market in 2022.


• ACG Worldwide Pvt., Ltd., BioCaps Enterprise, Bright Caps GmbH, Bright Pharmacaps Inc., Capscanada Corporation, Capsugel, Inc., Excellent Health Products Co., Ltd., Farmacapsulas S.A., Healthcaps India Limited, Natural Capsules Ltd., Qualicaps, Inc., Shanghai Honest Chem Co., Ltd., Shaoxing Kangke Capsule Co., Ltd., Suheung Co Ltd., Sunil Healthcare, Wuhan Carma Technology Co., Ltd, Zhejiang Yuexi Capsule Co., Ltd. and others